Recombinant gp100 protein presented by dendritic cells elicits a T- helper-cell response in vitro and in vivo

International Journal of Cancer

Volumn 83, Issue 4, 1999, Pages 547-554

  Cochlovius, Björn ^a   Linnebacher, Michael ^b   Zewe Welschof, Monika ^a   Zöller, Margot ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOLOGY; DENDRITIC CELL; HELPER CELL; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; TH1 CELLS; TRANSFECTION;

EID: 0032832761     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991112)83:4<547::AID-IJC18>3.0.CO;2-6     Document Type: Article

References (29)

1. ANICHINI, A., MORTARINI, R., MACCALLI, C, SQUARCINA, P., FLEISCHAUER, K., MASCHERONI, L. and PARMIANI, G., Cytotoxic T cells directed to the tumor antigens not on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol., 156, 208-217 (1996).
2. + T-cells in vitro and are APC for tumor-encoded antigens in vivo. J. Immunother., 21, 218-224 (1998).
3. ARNOLD, B., HORSTMANN, U., KUON, W., BÜRGERT, H.G., HÄMMERLING, G.J. and KVIST, S., Alloreactive cytolytic T-cell clones preferentially recognize conformational determinants on histocompatibility antigens: analysis with genetically engineered hybrid antigens. Proc. nat. Acad Sci. (Wash.), 82, 7030-7037 (1985).
4. BAKKER, A.B., MARLAND, G., DE BOER, A.J., HUIJBENS, R.J., DANEN, E.H., ADEMA, G.J. and FIGDOR, C.G., Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55, 5330-5334 (1995a).
5. BAKKER, A.B., SCHREURS, M.W., TAFFAZUL, G., DE BOER, A.J., KAWAKAMI, Y., ADEMA, G.J. and FIGDOR, C.G., Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer, 62, 97-102 (1995b).
6. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. exp. Med., 181, 619-629 (1995).
7. BRUSIC, V., HONEYMAN, G., HAMMER, J. and HARRISON, L., Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics, 14, 121-130 (1998).
8. CASTELLINO, F., ZHONG, G. and GERMAIN, R.N., Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking and the molecular basis of diverse determinant capture. Hum. Immunol., 54, 159-169 (1997).
9. CHEN, P. and ANATHASWAMY, H., Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J. Immunol., 151, 244-255 (1993).
10. COCHLOVIUS, B., PERSCHL, A., ADEMA, G.J. and ZÖLLER, M., Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bispecific antibody fragments. Int. J. Cancer, 81, 486-493 (1999).
11. CORMIER, J.N., HIJAZI, V.M., ABATI, A., FETSCH, P., BETTINOTTI, M., STEINBERG, S.M., ROSENBERG, S.A. and MARINCOLA, F.M., Heterogenous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer, 75, 517-524 (1998).
12. FAURE, F., EVEN, J. and KOURILSKY, P., Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit. Rev. Immunol., 18, 77-86 (1998).
13. + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. Crit. Rev. Immunol., 18, 87-98 (1998).
14. GUERDER, S. and MATZINGER, P., A fail-safe mechanism for maintaining self tolerance. J. exp. Med., 176, 553-564 (1992).
15. HALDER, T., PAWELEC, G., KIRKIN, A.F., ZEUTHEN, J., MEYER, H.E., KUN, L. and KALBACHER, H., Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res., 57, 3238-3244 (1997).
16. JÄGER, E., RINGHOFFER, M., DIENES, H.P., ARAND, M., KARBACH, J., JÄGER, D., ILSEMANN, C., HAGEDORN, M., OESCH, F. and KNUTH, A., Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer, 67, 54-62 (1996).
17. KAWAKAMI, Y. and ROSENBERG, S.A., Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol., 14, 173-192 (1997).
18. KOOPMANN, J.O., HÄMMERLING, G.J. and MOMBURG, F., Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Curr. Opin. Immunol., 9, 80-88 (1997).
19. LIN, K.-Y., GUARNIERI, F., STAVELEY-U'CARROLL, K., LEVITZKY, H., AUGUST, J., PARDOLL, D. and WU, T.C., Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56, 21-26 (1996).
20. 4 cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med., 189, 871-876 (1999).
21. OLSEN, A.C., FOSSUM, B., KIRKIN, A.F., ZEUTHEN, J. and GAUDERNACK, G., A human melanoma line, recognized by both HLA class I and II restricted T cells, is capable of initiating both primary and secondary immune responses. Scand. J. Immunol., 41, 357-364 (1995).
22. PARKHURST, M.R., SALGALLER, M.L., SOUTHWOOD, S., ROBBINS, P.F., SETTE, A., ROSENBERG, S.A. and KAWAKAMI, Y., Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157, 2539-2548 (1996).
23. PAWELEC, G., ZEUTHEN, J. and KIESSLING, R., Escape from host-antitumor immunity. Crit. Rev. Oncol., 8, 111-141 (1997).
24. PETERS, R.H., GIESELER, R., THIELE, B. and STEINBACH, P., Dendritic cells: from ontogenic orphans to myelomonocytic descendants. Immunol. Today, 17, 273-278 (1996).
25. PULARSKI, B.A. and OSTRAND-ROSENBERG, S., Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res., 58, 1486-1493 (1998).
26. ROSENBERG, S.A. AND 15 OTHERS, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature (Med.), 4, 321-327 (1998).
27. SKIPPER, J.C., KITTLESEN, D.J., HENDRICKSON, R.C., DEACON, D.D., HARTHUN, N.L., WAGNER, S.N., HUNT, D.F., ENGELHARD, V.H. and SLINGLUFF, C.L., Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel17/gp100. J. Immunol., 157, 5027-5033 (1996).
28. TSAI, V., SOUTHWOOD, S., SIDNEY, J., SAKAGUCHI, K., KAWAKAMI, Y., APPELLA, E., SETTE, A. and CELIS, E., Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigens by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol., 158, 1796-1802 (1997).
29. ZAROUR, H., DE SMET, C., LEHMANN, R, MARCHAND, M., LETHE, B., ROMERO, P., BOON, T. and RENAULD, J.C., The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from Pmel17/gp100. J. invest. Dermatol., 107, 63-67 (1996).